Do Regulatory Changes Seriously Affect the Medical Devices Industry? Evidence From the Czech Republic

Background: Within the EU, some of the challenges and perceived risks now facing medical device (MD) developers result from changes in the regulatory framework, emphasizing safety. Therefore, medical technology companies must adopt stricter quality assurance measures so that individual devices can b...

Full description

Saved in:
Bibliographic Details
Main Authors: Petra Maresova (Author), Lukas Rezny (Author), Lukas Peter (Author), Ladislav Hajek (Author), Frank Lefley (Author)
Format: Book
Published: Frontiers Media S.A., 2021-04-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_aa628d42a7cf460b81c3e3f9d66a9ce9
042 |a dc 
100 1 0 |a Petra Maresova  |e author 
700 1 0 |a Lukas Rezny  |e author 
700 1 0 |a Lukas Peter  |e author 
700 1 0 |a Ladislav Hajek  |e author 
700 1 0 |a Frank Lefley  |e author 
245 0 0 |a Do Regulatory Changes Seriously Affect the Medical Devices Industry? Evidence From the Czech Republic 
260 |b Frontiers Media S.A.,   |c 2021-04-01T00:00:00Z. 
500 |a 2296-2565 
500 |a 10.3389/fpubh.2021.666453 
520 |a Background: Within the EU, some of the challenges and perceived risks now facing medical device (MD) developers result from changes in the regulatory framework, emphasizing safety. Therefore, medical technology companies must adopt stricter quality assurance measures so that individual devices can be speedily tracked and retrieved in emergency situations.Objectives: We highlight the challenges and risks faced by the European medical devices industry, particularly those faced by SMEs in the Czech Republic. We address two important research questions: Q1. Do advantages from increased regulation outweigh the additional expenses? Q2. As many MD developers are SMEs, will the new regulatory regime result in some of those companies going out of business and therefore impede future innovation?Methods: The paper focuses on a single case study, with the situation and outcomes discussed in the context of the financial results of a further 50 medical device manufacturers marketing in the Czech Republic.Results: Our findings suggest that the new legislation will result in improved safety, facilitate product recalls, but the cost and administrative burden may be high. The evidence also indicates that some SMEs may be forced to diversify to "non-medical" products, with the inevitable loss of innovative MDs being made available to patients and healthcare providers. 
546 |a EN 
690 |a risk 
690 |a patient safety 
690 |a regulation 
690 |a innovation 
690 |a SME 
690 |a medical devices 
690 |a Public aspects of medicine 
690 |a RA1-1270 
655 7 |a article  |2 local 
786 0 |n Frontiers in Public Health, Vol 9 (2021) 
787 0 |n https://www.frontiersin.org/articles/10.3389/fpubh.2021.666453/full 
787 0 |n https://doaj.org/toc/2296-2565 
856 4 1 |u https://doaj.org/article/aa628d42a7cf460b81c3e3f9d66a9ce9  |z Connect to this object online.